Garivulimab (Anti-B7-H1 / PD-L1 / CD274)
Garivulimab (Anti-B7-H1 / PD-L1 / CD274) (A2778-GRP)
Products
Description
Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2778 |
| Target | PD-1/PD-L1 |